lazertinib

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

lazertinib
Mar 27, 2025, 14:29 | Blog
Novel ways to mitigate the toxicity associated with combination therapy for EGFR-mutant advanced NSCLC - ESMO
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "Two studies presented…
Mar 26, 2025, 16:35 | Drugs
MARIPOSA trial results presented at ELCC25 - BREAKING from Paris
MARIPOSA reports OS benefit with amivantamab–lazertinib vs osimertinib monotherapy! This year, the European Lung Cancer…
Mar 26, 2025, 13:38 | Blog
Antonio Calles: Final overall survival of MARIPOSA trial
Antonio Calles, Head of the Lung Cancer Unit at Ruber International Hospital, shared a post…
Mar 25, 2025, 12:21 | Insight
Great Debates in Solid Tumors 2025 - Insights from Estela Rodriguez
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of…
Mar 3, 2025, 10:24 | Blog
ASCO's new living guideline update for Stage IV NSCLC with Driver Alterations
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "The American Society of…
Jan 9, 2025, 03:44 | Insight
Amol Akhade: Mariposa shows significant OS benifit
Amol Akhade, A Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance…
Jan 3, 2025, 21:19 | Science
Luis Raez: We have a lot of survivors on osimertinib alone that will need second-line therapy in the future
Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post…
Jan 3, 2025, 16:25 | Science
Amivantamab Plus Lazertinib in Patients With EGFR-mutant NSCLC by Benjamin Besse et al.
A recent article by Benjamin Besse et al. was mentioned by Akhil Santhosh, Medical Oncology Specialist at…
Dec 31, 2024, 19:54 | Blog
Antonio Passaro: An important milestone in the treatment of advanced NSCLC with common EGFR mutations
Antonio Passaro, Medical oncologist at the European Institute of Oncology in Milan, posted on LinkedIn:…
Dec 17, 2024, 16:18 | Insight
Update on U.S. Regulatory Review of Subcutaneous Amivantamab
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has issued a…
Dec 11, 2024, 17:56 | Insight
Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn: “A Year…
Sep 11, 2024, 16:13 | Insight
RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT plus LAZCLUZE regimen compared…
Sep 10, 2024, 13:45 | Societies
Rami Manochakian's key highlights from WCLC24
WCLC is a major international event focused on the latest advancements in lung cancer research,…
Sep 9, 2024, 09:55 | Societies
Insights from WCLC24 by Chul Kim
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Aug 29, 2024, 17:43 | Insight
FDA’s latest approvals summarized by Samuel Hume
Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…
Aug 24, 2024, 11:47 | Insight
Narjust Florez: Discussion with Julia Rotow about the MARIPOSA trial
Narjust Florez shared a post by IASLC on X, adding: “At The International Association for…
Aug 24, 2024, 11:15 | Insight
Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…
Aug 23, 2024, 14:21 | Drugs
Stephen V Liu: How do we select the optimal regimen for EGFR NSCLC?
Stephen V Liu shared on X: "With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and…
Aug 22, 2024, 14:00 | Insight
Jarushka Naidoo: Phase II Lazertinib in EGFR+ NSCLC with CNS disease
Jarushka Naidoo shared a post on X: “Phase II Lazertinib in EGFR+ NSCLC with CNS disease,…
Aug 21, 2024, 17:08 | Insight
What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC
On August 19, 2024, the FDA approved a new combination therapy for advanced non-small cell…
Jul 19, 2024, 22:55 | Blog
What after Osimertinib failure?
Abhishek Pathak, Professor at the Indian Army, shared a post on X: "What after Osimertinib…
Jul 1, 2024, 15:01 | Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 28, 2024, 11:08 | Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 21, 2024, 10:50 | Blog
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "Out in…
Jun 13, 2024, 15:48 | Insight
Stephen Liu on a paper by Natasha Leighl, et al.
Stephen Liu recently shared a post on X: "PALOMA-3 results at Journal of Clinical Oncology…
Jun 2, 2024, 09:09 | Societies
15 Posts From ASCO24 Day 2 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
May 29, 2024, 12:03 | Insight
Eric Singhi: MARIPOSA a path forward to help us determine who benefits from 1L combination therapy?
Eric Singhi shared on X:  "MARIPOSA: Amivantamab + lazertinib v osimertinib in 1L EGFR+ mNSCLC:…
May 28, 2024, 08:21 | Blog
Antonio Passaro's top 10 selection with explanation, among the lung cancer abstracts from ASCO24
Antonio Passaro, shared a post on X: ''ASCO24 is ready to start soon! Here, my top…
May 27, 2024, 04:19 | Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
Oct 29, 2023, 03:16 | Drugs
Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "ESMO23 is…
All: 30 Posts: 1 - 100
Special Coverage